Work

Facteurs déterminants à l’utilisation des inhibiteurs du DPP-4 en médecine générale : enquête observationnelle de pratique auprès des médecins généralistes isérois concernant leur première intention de bithérapie chez les patients diabétiques de type 2 et l’évolution de prescription des antidiabétiques oraux ; des sulfamides aux inhibiteurs des DPP-4 en première intention

Year: 2023
Type: dissertation
Study design: Observational Study
Abstract: INTRODUCTION: Type 2 diabetes is a major public health issue affecting 3.6 million patients in France. Complications affect the macro- and micro-vascular systems with cardiovascular, renal, ophthalmological and nervous system damage. To reduce these complications, it is necessary to control glycated haemoglobin, which is achieved through hygienic and dietary measures and drug treatments. Drug treatments have multiplied to allow an effective therapeutic intensification on HbA1c. The growing number of treatments creates a gap between specialized and national recommendations, with the emergence of incretins. In order to centralize the therapeutic management of patients, the role of general practitioners has become essential, but is constrained by the multiplicity of resources. The main objective of this thesis is to determine which drug treatment is associated with Metformin in first line. The secondary objectives are to define the determining factors of this choice and to evaluate the evolution of prescribing practices. MATERIAL AND METHOD: A cross-sectional observational study was conducted from July to August 2022. A questionnaire was sent to general practitioners in Isère among the author's acquaintances. RESULTS: Thirty-one general practitioners participated. The first therapeutic class associated with Metformin was DPP-4 inhibitors, followed by sulfonamides. The main determinants of this choice were ease of compliance, absence of weight gain and hypoglycemia. Physicians were aware of the HAS and SFD recommendations, but 29% did not know which of the two they used. For 2/3 of the physicians, the evolution of practice was towards DPP-4 inhibitors for less than 5 years. Lack of background, adverse effects, and lack of hindsight were the main obstacles to this evolution. CONCLUSIONS:This study highlights a slower use of new molecules by general practitioners. Their integration into the overall care of the patient is complex with a lack of knowledge of general practitioners and a distrust about new molecules. Therapeutic efficacy on glycated hemoglobin does not appear to be central for decision-making, whereas it is at the origin of the intensification of treatments. A gap between the practice of general practitioners and specialists appears and may be the subject of future studies.
Source: HAL
Author: Cuney, Laetitia
Language: French
Field: Medicine
Open Access status: green
OpenAlex ID: W7113334172
Cites: 42
Cited by:
Related to: 10